Savara (NASDAQ:SVRA) Shares Climb 7.2% - Still a Buy?

Key Points

• Savara shares rose 7.2% to about $4.99, although trading volume was 78% below the stock’s average daily volume.
• Analyst views remain mixed, but the consensus is a “Moderate Buy” with an average price target of $10.25; JPMorgan initiated coverage with an “overweight” rating and a $12 target, while some firms maintained or issued sell ratings.
• Savara remains a clinical-stage biotech focused on molgramostim for rare lung disease, and its latest quarterly loss of $0.16 per share exceeded the expected loss of $0.14. Institutional investors own approximately 87.9% of the company.

Savara Inc. (NASDAQ:SVRA - Get Free Report)'s share price rose 7.2% during mid-day trading on Wednesday. The company traded as high as $5.05 and last traded at $4.9850. 360,182 shares were traded during trading, a decline of 78% from the average daily volume of 1,671,651 shares. The stock had previously closed at $4.65.

Wall Street Analysts Forecast Growth

SVRA has been the subject of several recent analyst reports. JPMorgan Chase & Co. assumed coverage on Savara in a research report on Wednesday. They set an "overweight" rating and a $12.00 price objective for the company. Wall Street Zen cut Savara from a "hold" rating to a "sell" rating in a research report on Sunday. Citigroup reissued a "market outperform" rating on shares of Savara in a research note on Wednesday. Weiss Ratings restated a "sell (d-)" rating on shares of Savara in a research note on Friday, July 17th. Finally, Royal Bank Of Canada set a $10.00 price target on shares of Savara in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $10.25.

Savara Trading Up 8.3%

The business has a fifty day moving average of $5.35 and a 200-day moving average of $5.42. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13. The company has a market capitalization of $1.03 billion, a P/E ratio of -8.68 and a beta of 0.20.

Savara (NASDAQ:SVRA - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Analysts anticipate that Savara Inc. will post -0.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Savara

Large investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. purchased a new stake in Savara during the first quarter valued at about $57,000. Sequoia Financial Advisors LLC bought a new stake in shares of Savara in the 2nd quarter valued at about $69,000. E Fund Management Co. Ltd. bought a new stake in shares of Savara in the 2nd quarter valued at about $77,000. Sanctuary Advisors LLC purchased a new stake in Savara during the 2nd quarter valued at about $87,000. Finally, Inceptionr LLC purchased a new stake in Savara during the 1st quarter valued at about $84,000. Institutional investors own 87.93% of the company's stock.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.